xssr9qkm

Property	Value
?:abstract	BACKGROUND: The impact of corticosteroid therapy on outcomes of patients with coronavirus disease 2019 (COVID-19) is highly controversial. We aimed to compare the risk of death between COVID-19-related ARDS patients with corticosteroid treatment and those without. METHODS: In this single-center retrospective observational study, patients with ARDS caused by COVID-19 between January 20, 2020, and February 24, 2020, were enrolled. The primary outcome was 60-day in-hospital death. The exposure was prescribed systemic corticosteroids or not. Time-dependent Cox regression models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for 60-day in-hospital mortality. RESULTS: A total of 382 patients [60.7 ± 14.1 years old (mean ± SD), 61.3% males] were analyzed. The median of sequential organ failure assessment (SOFA) score was 2.0 (IQR 2.0-3.0). Of these cases, 94 (24.6%) patients had invasive mechanical ventilation. The number of patients received systemic corticosteroids was 226 (59.2%), and 156 (40.8%) received standard treatment. The maximum dose of corticosteroids was 80.0 (IQR 40.0-80.0) mg equivalent methylprednisolone per day, and duration of corticosteroid treatment was 7.0 (4.0-12.0) days in total. In Cox regression analysis using corticosteroid treatment as a time-varying variable, corticosteroid treatment was associated with a significant reduction in risk of in-hospital death within 60 days after adjusting for age, sex, SOFA score at hospital admission, propensity score of corticosteroid treatment, comorbidities, antiviral treatment, and respiratory supports (HR 0.42; 95% CI 0.21, 0.85; p = 0.0160). Corticosteroids were not associated with delayed viral RNA clearance in our cohort. CONCLUSION: In this clinical practice setting, low-dose corticosteroid treatment was associated with reduced risk of in-hospital death within 60 days in COVID-19 patients who developed ARDS. Background: The impact of corticosteroid therapy on outcomes of patients with coronavirus disease 2019 (COVID-19) is highly controversial We aimed to compare the risk of death between COVID-19-related ARDS patients with corticosteroid treatment and those without Methods: In this single-center retrospective observational study, patients with ARDS caused by COVID-19 between January 20, 2020, and February 24, 2020, were enrolled The primary outcome was 60-day in-hospital death The exposure was prescribed systemic corticosteroids or not Time-dependent Cox regression models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for 60-day in-hospital mortality Results: A total of 382 patients [60 7 ± 14 1 years old (mean ± SD), 61 3% males] were analyzed The median of sequential organ failure assessment (SOFA) score was 2 0 (IQR 2 0–3 0) Of these cases, 94 (24 6%) patients had invasive mechanical ventilation The number of patients received systemic corticosteroids was 226 (59 2%), and 156 (40 8%) received standard treatment The maximum dose of corticosteroids was 80 0 (IQR 40 0–80 0) mg equivalent methylprednisolone per day, and duration of corticosteroid treatment was 7 0 (4 0–12 0) days in total In Cox regression analysis using corticosteroid treatment as a time-varying variable, corticosteroid treatment was associated with a significant reduction in risk of in-hospital death within 60 days after adjusting for age, sex, SOFA score at hospital admission, propensity score of corticosteroid treatment, comorbidities, antiviral treatment, and respiratory supports (HR 0 42;95% CI 0 21, 0 85;p = 0 0160) Corticosteroids were not associated with delayed viral RNA clearance in our cohort Conclusion: In this clinical practice setting, low-dose corticosteroid treatment was associated with reduced risk of in-hospital death within 60 days in COVID-19 patients who developed ARDS
is ?:annotates of	<https://research.tib.eu/covid-19/entity/xssr9qkm_hasAnnotation_C0035736> <https://research.tib.eu/covid-19/entity/xssr9qkm_hasAnnotation_C1825598>
?:creator	<https://research.tib.eu/covid-19/entity/Wu%2C_C.%3B_Hou%2C_D.%3B_Du%2C_C.%3B_Cai%2C_Y.%3B_Zheng%2C_J.%3B_Xu%2C_J.%3B_Chen%2C_X.%3B_Chen%2C_C.%3B_Hu%2C_X.%3B_Zhang%2C_Y.%3B_Song%2C_J.%3B_Wang%2C_L.%3B_Chao%2C_Y._C.%3B_Feng%2C_Y.%3B_Xiong%2C_W.%3B_Chen%2C_D.%3B_Zhong%2C_M.%3B_Hu%2C_J.%3B_Jiang%2C_J.%3B_Bai%2C_C.%3B_Zhou%2C_X.%3B_Song%2C_Y.%3B_Gong%2C_F.> <https://research.tib.eu/covid-19/entity/Wu%2C_Chaomin%3B_Hou%2C_Dongni%3B_Du%2C_Chunling%3B_Cai%2C_Yanping%3B_Zheng%2C_Junhua%3B_Xu%2C_Jie%3B_Chen%2C_Xiaoyan%3B_Chen%2C_Cuicui%3B_Hu%2C_Xianglin%3B_Zhang%2C_Yuye%3B_Song%2C_Juan%3B_Wang%2C_Lu%3B_Chao%2C_Yen-Cheng%3B_Feng%2C_Yun%3B_Xiong%2C_Weining%3B_Chen%2C_Dechang%3B_Zhong%2C_Ming%3B_Hu%2C_Jie%3B_Jiang%2C_Jinjun%3B_Bai%2C_Chunxue%3B_Zhou%2C_Xin%3B_Xu%2C_Jinfu%3B_Song%2C_Yuanlin%3B_Gong%2C_Fengyun>
?:journal	Crit_Care Critical_Care
?:license	unk
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/xssr9qkm_HAS_C5203670_CAUSES_C0035222>
?:source	WHO
?:title	Corticosteroid therapy for coronavirus disease 2019-related acute respiratory distress syndrome: a cohort study with propensity score analysis
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:who_covidence_id	#1067255 #917937
?:year	2020

Property

Value

?:abstract

BACKGROUND: The impact of corticosteroid therapy on outcomes of patients with coronavirus disease 2019 (COVID-19) is highly controversial. We aimed to compare the risk of death between COVID-19-related ARDS patients with corticosteroid treatment and those without. METHODS: In this single-center retrospective observational study, patients with ARDS caused by COVID-19 between January 20, 2020, and February 24, 2020, were enrolled. The primary outcome was 60-day in-hospital death. The exposure was prescribed systemic corticosteroids or not. Time-dependent Cox regression models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for 60-day in-hospital mortality. RESULTS: A total of 382 patients [60.7 ± 14.1 years old (mean ± SD), 61.3% males] were analyzed. The median of sequential organ failure assessment (SOFA) score was 2.0 (IQR 2.0-3.0). Of these cases, 94 (24.6%) patients had invasive mechanical ventilation. The number of patients received systemic corticosteroids was 226 (59.2%), and 156 (40.8%) received standard treatment. The maximum dose of corticosteroids was 80.0 (IQR 40.0-80.0) mg equivalent methylprednisolone per day, and duration of corticosteroid treatment was 7.0 (4.0-12.0) days in total. In Cox regression analysis using corticosteroid treatment as a time-varying variable, corticosteroid treatment was associated with a significant reduction in risk of in-hospital death within 60 days after adjusting for age, sex, SOFA score at hospital admission, propensity score of corticosteroid treatment, comorbidities, antiviral treatment, and respiratory supports (HR 0.42; 95% CI 0.21, 0.85; p = 0.0160). Corticosteroids were not associated with delayed viral RNA clearance in our cohort. CONCLUSION: In this clinical practice setting, low-dose corticosteroid treatment was associated with reduced risk of in-hospital death within 60 days in COVID-19 patients who developed ARDS.
Background: The impact of corticosteroid therapy on outcomes of patients with coronavirus disease 2019 (COVID-19) is highly controversial We aimed to compare the risk of death between COVID-19-related ARDS patients with corticosteroid treatment and those without Methods: In this single-center retrospective observational study, patients with ARDS caused by COVID-19 between January 20, 2020, and February 24, 2020, were enrolled The primary outcome was 60-day in-hospital death The exposure was prescribed systemic corticosteroids or not Time-dependent Cox regression models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for 60-day in-hospital mortality Results: A total of 382 patients [60 7 ± 14 1 years old (mean ± SD), 61 3% males] were analyzed The median of sequential organ failure assessment (SOFA) score was 2 0 (IQR 2 0–3 0) Of these cases, 94 (24 6%) patients had invasive mechanical ventilation The number of patients received systemic corticosteroids was 226 (59 2%), and 156 (40 8%) received standard treatment The maximum dose of corticosteroids was 80 0 (IQR 40 0–80 0) mg equivalent methylprednisolone per day, and duration of corticosteroid treatment was 7 0 (4 0–12 0) days in total In Cox regression analysis using corticosteroid treatment as a time-varying variable, corticosteroid treatment was associated with a significant reduction in risk of in-hospital death within 60 days after adjusting for age, sex, SOFA score at hospital admission, propensity score of corticosteroid treatment, comorbidities, antiviral treatment, and respiratory supports (HR 0 42;95% CI 0 21, 0 85;p = 0 0160) Corticosteroids were not associated with delayed viral RNA clearance in our cohort Conclusion: In this clinical practice setting, low-dose corticosteroid treatment was associated with reduced risk of in-hospital death within 60 days in COVID-19 patients who developed ARDS

is ?:annotates of